A phase Ib study of investigational pan-RAF kinase inhibitor MLN2480 plus investigational TORC1/2 inhibitor MLN0128, investigational Aurora A kinase inhibitor alisertib (MLN8237), or paclitaxel in patients (pts) with advanced solid tumors.

Anthony J Olszanski,Rastilav Bahleda,Rebecca Suk Heist,Teresa Macarulla,Lakshmi Rangachari,Viviana Bozón,Michelle Kneissl,Mark R Middleton,Xiaofei Zhou

doi:10.1200/jco.2015.33.15_suppl.tps2609

A phase Ib study of investigational pan-RAF kinase inhibitor MLN2480 plus investigational TORC1/2 inhibitor MLN0128, investigational Aurora A kinase inhibitor alisertib (MLN8237), or paclitaxel in patients (pts) with advanced solid tumors.

Anthony J Olszanski, Rastilav Bahleda + Show 7 more

https://doi.org/10.1200/jco.2015.33.15_suppl.tps2609

Copy DOI

Export

Save

Cite

Journal: Journal of Clinical Oncology	Publication Date: May 20, 2015
Citations: 1

Affiliation: Fox Chase Cancer Center, Institut Gustave Roussy, Massachusetts General Hospital, Vall d'Hebron Hospital Universitari, Millennium Engineering and Integration (United States), Oxford University Hospitals NHS Trust

#Kinase Inhibitor Alisertib #ERK Signaling Cascade #Investigational Aurora #Inhibitor MLN0128 #Paclitaxel In Patients #Advanced Solid Tumors #Kinase Inhibitor #Advanced Tumors #pan-RAF Kinase Inhibitor #pan-RAF Kinase

Abstract
Full-Text
Similar Papers

Abstract

Listen

TPS2609 Background: Signaling hyperactivation secondary to MAPK pathway aberrations are common. RAF kinases play key roles in the RAS/RAF/MEK/ERK signaling cascade, representing potentially valid t...

Full Text

Published Version

Check institute access

Open DOI Link

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title

Journal

Date

Author

View more papers

More From: Journal of Clinical Oncology

Paper Title

Journal

Date

Author

View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.

R Discovery Prime

A phase Ib study of investigational pan-RAF kinase inhibitor MLN2480 plus investigational TORC1/2 inhibitor MLN0128, investigational Aurora A kinase inhibitor alisertib (MLN8237), or paclitaxel in patients (pts) with advanced solid tumors.